Caroline Hensley Joins Xilio Therapeutics As New Chief Legal Officer

Xilio Therapeutics, Inc. is a clinical-stage biotech company developing tumor-activated immuno-oncology therapies for cancer treatment. The firm has announced the appointment of Caroline (Holda) Hensley as its new Chief Legal Officer.

René Russo, Pharm.D., president and chief executive officer of Xilio, commented, “Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialisation. Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.”

Ms Hensley brings extensive experience to the role, as she has formerly served as Senior Vice President, Assistant General Counsel, and Chief Compliance Officer at Seres Therapeutics, Inc. During her tenure, she managed legal and compliance matters across capital markets, licensing deals, clinical development, commercial launches, partnerships, and FDA regulatory compliance. 

Earlier in her career, she worked as a corporate associate at Latham & Watkins’ Boston office, advising biotech and other industries on capital markets and strategic transactions. Ms. Hensley holds a B.A. in economics from the University of Texas at Austin and pursued her J.D. at Boston University School of Law.

Ms. Caroline Hensley expressed her excitement regarding her appointment, saying, “I am thrilled to join the Xilio team at this pivotal moment in the company's growth and look forward to helping to advance Xilio’s promising pipeline of novel, tumour-activated immuno-oncology therapies.”